AlphAIAlphAI — Financial news for AI agents
investing.comSEP 151 min read$RMD

ResMed stock jumps 3% on RBC Capital upgrade to Outperform

ResMed Inc (RMD) shares rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. The upgrade cited ResMed's leadership in sleep apnea devices, strong Q4 growth, and FDA recall of a competitor's device. RBC expects high single-digit EPS growth over three years.

Original reporting
investing.com
Published Sep 15, 2026, 7:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$RMD
Bullish
high confidence
Mentioned
$RMD
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RMDBullishHigh
01

Why it matters

Analyst upgrade reflects confidence in market share gains and capital management focus.

02

Market read

ResMed's stock reacts positively to the upgrade, indicating short‑term buying interest.

03

What to watch

Potential supply‑chain constraints and regulatory recall environment could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

ResMed reported 8% YoY growth in Americas sleep devices and 13% globally in Q4 FY2026.

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

RBC Capital upgraded ResMed to Outperform and raised the price target to $262, prompting a 3% stock rise.

Expected impact

Potential further 2‑4% gain if momentum continues.

Evidence & confidence

Analyst cites market leadership and strong Q4 growth; price target increase reinforces bullish view.

Market effects

Sector

Sleep‑apnea device sector may see broader uplift as ResMed leads with growth.

Regional

U.S. medical‑device stocks could benefit from the upgrade.

Global

Limited to ResMed and peers; no major macro effect.

Counterpoint

What could challenge this read

Upgrade may be premature if competition intensifies or Philips returns stronger than expected.

Key entities

  • analyst_firm
    RBC Capital Markets

    Upgraded ResMed to Outperform and raised price target.

  • company
    ResMed Inc.

    Medical‑device maker specializing in sleep‑apnea equipment.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 28
$RMDMed

Health Check: No 'Wharfie Time' curse as healthcare stocks kick away from the pack

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

stockhead.com.au5 min
SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
SEP 16
$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min
SEP 15
$RMDHighAI 8/10

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

investing.com2 min
SEP 14
$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min